HUMIRA (adalimumab) biosimilars will have significant uptake in the EU with pricing at 10-20% lower than the originator brand across the EU, according to a report from analytics company GlobalData.
This will be further facilitated by the quotas that healthcare authorities have in place for biosimilar prescription, says the report, referencing UK quotas at 80%-90% of patients within the first 12 months of a biosimilar launch.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 18
